(S,R,S)-AHPC-CO-PEG4-COOH is a specialized E3 Ligase Ligand-Linker Conjugate designed for use in the synthesis of PROTACs (Proteolysis Targeting Chimeras). This molecule consists of the potent VHL (Von Hippel-Lindau) E3 ligase ligand AHPC, tethered via a PEG4 (tetraethylene glycol) spacer to a carboxylic acid functional group. The flexible PEG4 linker enhances solubility and provides optimal spatial orientation when conjugating with target protein ligands, enabling efficient ubiquitination and subsequent proteasomal degradation of disease-associated proteins. As a premium reagent in the rapid development of PROTAC therapeutics, (S,R,S)-AHPC-CO-PEG4-COOH is widely applicable in drug discovery research targeting difficult-to-drug oncogenic proteins and other intracellular targets. This compound is essential for researchers creating bifunctional molecules that harness the cell's own degradation machinery, advancing the frontier of targeted protein degradation.
Structure of 2172820-12-9
* For research and manufacturing use only. Not for human or clinical use.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Background Introduction
(S,R,S)-AHPC-CO-PEG4-COOH is a specialized E3 ligase ligand-linker conjugate commonly utilized in the design of PROTACs (Proteolysis Targeting Chimeras). This compound incorporates the high-affinity AHPC ligand, which targets the Von Hippel-Lindau (VHL) E3 ubiquitin ligase, and features a hydrophilic PEG4 spacer terminating in a carboxylic acid functional group. Its structure is optimally suited for enhancing PROTAC development, enabling targeted protein degradation in medicinal chemistry and chemical biology research.
Mechanism
(S,R,S)-AHPC-CO-PEG4-COOH functions as a bifunctional molecular module in PROTAC design. The AHPC moiety selectively binds to the VHL E3 ubiquitin ligase, while the PEG4 linker offers structural flexibility and improved solubility. The C-terminal carboxylic acid acts as a reactive handle, allowing for efficient conjugation to target protein ligands via robust coupling techniques. Once incorporated into a PROTAC, this conjugate brings the VHL ligase into proximity with a disease-relevant target protein, triggering ubiquitination and proteasomal degradation of the target protein.
Applications
(S,R,S)-AHPC-CO-PEG4-COOH is primarily used as a key intermediate in the synthesis of VHL-based PROTAC molecules, facilitating the development of next-generation drugs that induce selective protein degradation. Its extended PEG4 linker enhances pharmacokinetic properties and cellular permeability. Researchers leverage this conjugate for the discovery and optimization of chemical probes and therapeutics across oncology, neurodegenerative diseases, and immune disorders by enabling rapid prototyping and customization of PROTACs targeting diverse pathogenic proteins.
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Please contact us with any specific requirements and we will get back to you as soon as possible.